| DB ID | MyCo_1141 |
| Title | CLINICAL UTILITY OF BETA-D-GLUCAN TESTING FOR ENDOGENOUS FUNGAL CHORIORETINITIS OR ENDOPHTHALMITIS |
| Year | 2021 |
| PMID | 32516224 |
| Fungal Diseases involved | Endogenous fungal chorioretinitis |
| Associated Medical Condition | None |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Pennsylvania |
| Cohort | Cases included six chorioretinitis and four endophthalmitis patients. Controls included 78 patients without chorioretinitis or endophthalmitis. |
| Cohort No. | 6 Patients and 78 control |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.667 |
| Specificity | 0.859 |
| Positive Predictive Value | 0.038 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | BDG assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | BDG Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
